ID

22146

Descripción

EMD 521873 in Advanced Solid Tumors, MTD Finding; ODM derived from: https://clinicaltrials.gov/show/NCT01032681

Link

https://clinicaltrials.gov/show/NCT01032681

Palabras clave

Versiones (1)
  1. 21/5/17 21/5/17 -
Subido en

21 de mayo de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Non-Hodgkin Lymphoma NCT01032681

Inglés

Eligibility Non-Hodgkin Lymphoma NCT01032681

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. signed written informed consent
Descripción

informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
2. male or female, aged ≥ 18 years, inpatient for treatment phase of cycle 1 and 2, outpatient treatment possible for subsequent cycles
Descripción

gender, age, treatment cycle

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
UMLS CUI [3]
C1302181
3. histologically or cytologically proven metastatic or locally advanced solid tumors (epithelial or mesenchymal cancers) or b-cell non-hodgkin lymphoma for which no standard therapy exists or after failure of standard therapy
Descripción

metastatic or locally advanced tumor, b-cell non-hogdkin lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2939420
UMLS CUI [2]
C0677984
UMLS CUI [3,1]
C0079731
UMLS CUI [3,2]
C0024305
4. eastern cooperative oncology group (ecog) performance status of 0 to 1 at study entry and an estimated life expectancy of at least 3 months
Descripción

ecog, life expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
UMLS CUI [2]
C0023671
5. adequate hematological function defined by wbc count ≥ 3 x 109/l with absolute neutrophil count (anc) ≥ 1.5 x 109/l and lymphocyte count ≥ 0.5 x 109/l; platelet count ≥100 x 109/l; hemoglobin ≥9 g/dl ( if the laboratory values for hemoglobin are outside the required entry level at screening, a patient may receive a transfusion of rbc. a stable hemoglobin level of ≥9 mg/dl for at least 7 days must be achieved prior to receiving the first dose of study medication.)
Descripción

hematologic function, wbc, anc, lymphocyte count, platelet count, hemoglobin

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0221130
UMLS CUI [1,2]
C0023508
UMLS CUI [1,3]
C0948762C0200635
UMLS CUI [1,4]
C0005821
UMLS CUI [1,5]
C0019046
6. adequate hepatic function defined by a total bilirubin level ≤ 1.5 times the upper limit of normal (uln) and aspartate-aminotransferase (ast) and alanine-aminotransferase (alt) levels ≤ 2.5 x uln or, for patients with documented metastatic disease to the liver, ast and alt levels ≤ 5 x uln
Descripción

hepatic function

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C1278039
UMLS CUI [1,3]
C0201836
UMLS CUI [1,4]
C0201899
7. no history of acute or chronic kidney disease and adequate renal function defined by an estimated creatinine clearance above 50 ml/min determined by 24-hour urine sampling or by the cockcroft-gault formula
Descripción

kidney function

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0232804
UMLS CUI [1,2]
C0812399
8. effective contraception for both male and female subjects if the risk of conception exists
Descripción

effective contraception

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. prior il-2 therapy within the last 6 months
Descripción

il-2 therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0199975
2. requirement for concurrent anticancer treatment (chemotherapy, radiotherapy, immune therapy, cytokine therapy except erythropoietin) or for concurrent systemic therapy with steroids or other immunosuppressive agents. short-term administration of steroids (i.e. for allergic reactions) is allowed.
Descripción

cancer treatment, immunosuppression

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C0021079
3. radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before the start of treatment in this study
Descripción

radiotherapy, chemotherapy, surgery, investigational drug

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1522449
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0543467
UMLS CUI [4]
C0013230
4. acquired immune defects such as human immunodeficiency virus (hiv)
Descripción

immunodeficiency

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021051
5. systemic autoimmune disease (e.g. lupus erythematodes, rheumatoid arthritis, addison's disease, autoimmune disease associated with lymphoma)
Descripción

autoimmune disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0004364
6. organ transplant recipients
Descripción

organ transplant recipient

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0376387
7. history of or active inflammatory bowel disease (e.g. crohn's disease, ulcerative colitis)
Descripción

inflammatory bowel disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021390
8. chronic viral infections (e.g. hepatitis b virus [hbv], hepatitis c virus [hcv])
Descripción

chronic viral infections

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0042769
UMLS CUI [1,2]
C0205191
9. uncontrolled hypertension (systolic >180 mmhg, diastolic >100 mmhg)
Descripción

uncontrolled hypertension

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1868885
10. known hypersensitivity reactions to any of the compounds of the study medication
Descripción

drug hypersensitivity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0013182
11. confirmed or clinically suspected brain metastases
Descripción

brain metastases

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0220650
12. pregnancy (absence to be confirmed by beta-human chorionic gonadotropin [β-hcg] test) or lactation period
Descripción

pregnancy, breast feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
13. clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident /stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure or serious cardiac arrhythmia requiring medication.
Descripción

cardiovascular disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007222
14. pulmonary disease which, in the opinion of the investigator, might impair the patient's respiratory tolerance to moderate pulmonary fluid overload (e.g. interstitial lung disease, severe chronic obstructive pulmonary disease)
Descripción

pulmonary disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0024115
15. all conditions which are associated with significant necroses of non tumor-bearing tissues like e.g. esophageal or gastroduodenal ulcers (< 6 months prior to enrolment), organ infarctions (< 6 months prior to enrolment) or active ischemic bowel disease
Descripción

necroses

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027540
16. presence of medically significant third space fluid (pericardial effusion or ascites/ pleural infusion requiring repetitive paracentesis)
Descripción

third space fluid

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0031039
UMLS CUI [2]
C0003962
UMLS CUI [3]
C0032227
17. known alcohol or drug abuse
Descripción

alcohol or drug abuse

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0038586
18. participation in another clinical trial within the past 30 days before start of study treatment
Descripción

study participation

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
19. all other significant diseases which, in the opinion of the investigator, might impair the patient's tolerance of study treatment.
Descripción

comorbidities

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009488
20. dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
Descripción

mental disorder

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0004936
Volver a la parte superior de la página

Similar models

Eligibility Non-Hodgkin Lymphoma NCT01032681

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
informed consent
Item
1. signed written informed consent
boolean
C0021430 (UMLS CUI [1])
gender, age, treatment cycle
Item
2. male or female, aged ≥ 18 years, inpatient for treatment phase of cycle 1 and 2, outpatient treatment possible for subsequent cycles
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C1302181 (UMLS CUI [3])
metastatic or locally advanced tumor, b-cell non-hogdkin lymphoma
Item
3. histologically or cytologically proven metastatic or locally advanced solid tumors (epithelial or mesenchymal cancers) or b-cell non-hodgkin lymphoma for which no standard therapy exists or after failure of standard therapy
boolean
C2939420 (UMLS CUI [1])
C0677984 (UMLS CUI [2])
C0079731 (UMLS CUI [3,1])
C0024305 (UMLS CUI [3,2])
ecog, life expectancy
Item
4. eastern cooperative oncology group (ecog) performance status of 0 to 1 at study entry and an estimated life expectancy of at least 3 months
boolean
C1520224 (UMLS CUI [1])
C0023671 (UMLS CUI [2])
hematologic function, wbc, anc, lymphocyte count, platelet count, hemoglobin
Item
5. adequate hematological function defined by wbc count ≥ 3 x 109/l with absolute neutrophil count (anc) ≥ 1.5 x 109/l and lymphocyte count ≥ 0.5 x 109/l; platelet count ≥100 x 109/l; hemoglobin ≥9 g/dl ( if the laboratory values for hemoglobin are outside the required entry level at screening, a patient may receive a transfusion of rbc. a stable hemoglobin level of ≥9 mg/dl for at least 7 days must be achieved prior to receiving the first dose of study medication.)
boolean
C0221130 (UMLS CUI [1,1])
C0023508 (UMLS CUI [1,2])
C0948762C0200635 (UMLS CUI [1,3])
C0005821 (UMLS CUI [1,4])
C0019046 (UMLS CUI [1,5])
hepatic function
Item
6. adequate hepatic function defined by a total bilirubin level ≤ 1.5 times the upper limit of normal (uln) and aspartate-aminotransferase (ast) and alanine-aminotransferase (alt) levels ≤ 2.5 x uln or, for patients with documented metastatic disease to the liver, ast and alt levels ≤ 5 x uln
boolean
C0232741 (UMLS CUI [1,1])
C1278039 (UMLS CUI [1,2])
C0201836 (UMLS CUI [1,3])
C0201899 (UMLS CUI [1,4])
kidney function
Item
7. no history of acute or chronic kidney disease and adequate renal function defined by an estimated creatinine clearance above 50 ml/min determined by 24-hour urine sampling or by the cockcroft-gault formula
boolean
C0232804 (UMLS CUI [1,1])
C0812399 (UMLS CUI [1,2])
effective contraception
Item
8. effective contraception for both male and female subjects if the risk of conception exists
boolean
C0700589 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
il-2 therapy
Item
1. prior il-2 therapy within the last 6 months
boolean
C0199975 (UMLS CUI [1])
cancer treatment, immunosuppression
Item
2. requirement for concurrent anticancer treatment (chemotherapy, radiotherapy, immune therapy, cytokine therapy except erythropoietin) or for concurrent systemic therapy with steroids or other immunosuppressive agents. short-term administration of steroids (i.e. for allergic reactions) is allowed.
boolean
C0920425 (UMLS CUI [1])
C0021079 (UMLS CUI [2])
radiotherapy, chemotherapy, surgery, investigational drug
Item
3. radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before the start of treatment in this study
boolean
C1522449 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0543467 (UMLS CUI [3])
C0013230 (UMLS CUI [4])
immunodeficiency
Item
4. acquired immune defects such as human immunodeficiency virus (hiv)
boolean
C0021051 (UMLS CUI [1])
autoimmune disease
Item
5. systemic autoimmune disease (e.g. lupus erythematodes, rheumatoid arthritis, addison's disease, autoimmune disease associated with lymphoma)
boolean
C0004364 (UMLS CUI [1])
organ transplant recipient
Item
6. organ transplant recipients
boolean
C0376387 (UMLS CUI [1])
inflammatory bowel disease
Item
7. history of or active inflammatory bowel disease (e.g. crohn's disease, ulcerative colitis)
boolean
C0021390 (UMLS CUI [1])
chronic viral infections
Item
8. chronic viral infections (e.g. hepatitis b virus [hbv], hepatitis c virus [hcv])
boolean
C0042769 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
uncontrolled hypertension
Item
9. uncontrolled hypertension (systolic >180 mmhg, diastolic >100 mmhg)
boolean
C1868885 (UMLS CUI [1])
drug hypersensitivity
Item
10. known hypersensitivity reactions to any of the compounds of the study medication
boolean
C0013182 (UMLS CUI [1])
brain metastases
Item
11. confirmed or clinically suspected brain metastases
boolean
C0220650 (UMLS CUI [1])
pregnancy, breast feeding
Item
12. pregnancy (absence to be confirmed by beta-human chorionic gonadotropin [β-hcg] test) or lactation period
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
cardiovascular disease
Item
13. clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident /stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure or serious cardiac arrhythmia requiring medication.
boolean
C0007222 (UMLS CUI [1])
pulmonary disease
Item
14. pulmonary disease which, in the opinion of the investigator, might impair the patient's respiratory tolerance to moderate pulmonary fluid overload (e.g. interstitial lung disease, severe chronic obstructive pulmonary disease)
boolean
C0024115 (UMLS CUI [1])
necroses
Item
15. all conditions which are associated with significant necroses of non tumor-bearing tissues like e.g. esophageal or gastroduodenal ulcers (< 6 months prior to enrolment), organ infarctions (< 6 months prior to enrolment) or active ischemic bowel disease
boolean
C0027540 (UMLS CUI [1])
third space fluid
Item
16. presence of medically significant third space fluid (pericardial effusion or ascites/ pleural infusion requiring repetitive paracentesis)
boolean
C0031039 (UMLS CUI [1])
C0003962 (UMLS CUI [2])
C0032227 (UMLS CUI [3])
alcohol or drug abuse
Item
17. known alcohol or drug abuse
boolean
C0038586 (UMLS CUI [1])
study participation
Item
18. participation in another clinical trial within the past 30 days before start of study treatment
boolean
C2348568 (UMLS CUI [1])
comorbidities
Item
19. all other significant diseases which, in the opinion of the investigator, might impair the patient's tolerance of study treatment.
boolean
C0009488 (UMLS CUI [1])
mental disorder
Item
20. dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
boolean
C0004936 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial